Long term use of eicosapentaenoic acid reduced major coronary events in hypercholesterolaemia

doi:10.1136/ebm.12.5.136

HOME

Author	Keyword(s)
Vol	Page
[Advanced]

Evidence-Based Medicine 2007;12:136; doi:10.1136/ebm.12.5.136
Copyright © 2007 by the BMJ Publishing Group Ltd.

This Article

	Full Text
	Full Text (PDF)
	Submit a response
	Alert me when this article is cited
	Alert me when eLetters are posted
	Alert me if a correction is posted

Services

	Email this article to a friend
	Similar articles in this journal
	Similar articles in PubMed
	Add article to my folders
	Download to citation manager
	Request Permissions

Citing Articles

	Citing Articles via Google Scholar

Google Scholar

	Articles by Newby, L K.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Newby, L K.

Topic Collections

	Relevant Article

Therapeutics

Long term use of eicosapentaenoic acid reduced major coronary events in hypercholesterolaemia

Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090–8.[CrossRef][Medline]

Q In Japanese patients with hypercholesterolaemia (HC), does long term use of eicosapentaenoic acid (EPA) reduce major coronary events?

Clinical impact ratings GP/FP/Primary care $*$ $*$ $*$ $*$ $*$ ${star}$ ${star}$ IM/Ambulatory care $*$ $*$ $*$ $*$ $*$ ${star}$ ${star}$ Cardiology $*$ $*$ $*$ $*$ $*$ ${star}$ ${star}$ Endocrine $*$ $*$ $*$ $*$ $*$ ${star}$ ${star}$

Key Words: coronary disease • eicosapentaenoic acid

The first 150 words of the full text of this article appear below.

METHODS
Design: randomised controlled trial (RCT) (Japan EPA Lipid InterventionStudy [JELIS]).

Allocation: {concealed^*}.

Blinding: blinded (outcome assessors, {data analysts, and data safetyand monitoring committee}).^*

Follow up period: mean 4.6 years.

Setting: Japan.

Patients: 18 645 patients 40–75 years of age (mean age 61 y, 69%postmenopausal women) from Japan with or without coronary arterydisease (previous myocardial infarction [MI], coronary interventions,or angina pectoris) who had a total cholesterol concentration $>=$ 6.5 mmol/l (low density lipoprotein [LDL] cholesterol concentration $>=$ 4.4 mmol/l). Exclusion criteria included acute MI, cardiovascular(CV) reconstruction, or cerebrovascular disorders in the past6 months; unstable angina; history or complication of seriousheart disease; complications of serious hepatic or renal disease;cancer; uncontrollable diabetes; hyperlipidaemia; haemorrhage;or hypersensitivity to study drug.

Intervention: EPA, 1800 mg/day with pravastatin, 10 mg/day (20 mg/d for seriousHC) or simvastatin, 5 mg/day (10 mg/d for serious HC) (n = . . . [Full text of this article]

L Kristin Newby, MD, MHS

Duke University Medical Center,
Durham, North Carolina, USA

Relevant Article

Glossary
Evid. Based Med. 2007 12: 160. (in Glossary) [Extract] [Full Text] [PDF]